search button
Open Access

Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple‑negative breast cancer treated with immune checkpoint inhibitors

  • Authors:
    • Jia'nan Cheng
    • Xiaofang Ding
    • Shouxia Xu
    • Bo Zhu
    • Qingzhu Jia

  • View Affiliations

  • Published online on: February 10, 2020     https://doi.org/10.3892/ol.2020.11381
  • Pages: 2817-2824

  • Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Triple‑negative breast cancer (TNBC) accounts for 15‑30% of all breast cancer cases and is clinically difficult to treat due to the lack of hormone or human epidermal growth factor receptor 2 receptors, which are usually targeted by the most successful therapeutic approaches. Immune checkpoint inhibitors (ICIs) have offered long‑term survival benefits in several types of solid tumors, however with low response rates. Thus, there is an urgent need to develop feasible biomarkers for identifying patients with TNBC, who are responsive. The present study demonstrated that the immune microenvironment of TNBC has the highest expression of immunoregulatory molecules among all pathologic types. The tumor mutation burden (TMB) of TNBC was not strongly correlated with cytolytic activity and showed no significant associations with different degrees of immune cell infiltration and TMB. The machine learning method divided patients with TNBC into two groups characterized by ‘hot’ and ‘cold’ tumors, according to whether immune‑associated genes were highly expressed, and different responses to immunotherapy were seen between these two groups. Furthermore, patients with a TP53MutPIK3CAWild genotype demonstrated favorable immunotherapy‑responsive signatures and may have improved outcomes with ICIs. In conclusion, the present study revealed that TP53 and PIK3CA may be appropriate biomarkers to screen for patients who would benefit most from ICIs, which could guide precise immunotherapy for patients with TNBC.
View Figures
View References

Related Articles

Journal Cover

April-2020
Volume 19 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Cheng J, Ding X, Xu S, Zhu B and Jia Q: Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple‑negative breast cancer treated with immune checkpoint inhibitors. Oncol Lett 19: 2817-2824, 2020.
APA
Cheng, J., Ding, X., Xu, S., Zhu, B., & Jia, Q. (2020). Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple‑negative breast cancer treated with immune checkpoint inhibitors. Oncology Letters, 19, 2817-2824. https://doi.org/10.3892/ol.2020.11381
MLA
Cheng, J., Ding, X., Xu, S., Zhu, B., Jia, Q."Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple‑negative breast cancer treated with immune checkpoint inhibitors". Oncology Letters 19.4 (2020): 2817-2824.
Chicago
Cheng, J., Ding, X., Xu, S., Zhu, B., Jia, Q."Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple‑negative breast cancer treated with immune checkpoint inhibitors". Oncology Letters 19, no. 4 (2020): 2817-2824. https://doi.org/10.3892/ol.2020.11381